324 related articles for article (PubMed ID: 27977334)
21. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
[TBL] [Abstract][Full Text] [Related]
22. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
[TBL] [Abstract][Full Text] [Related]
23. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital.
Elberdín L; Fernández-Torres R; Paradela S; Blanco E; Outeda M; Martín I; Fonseca E
J Dermatolog Treat; 2020 Nov; 31(7):698-701. PubMed ID: 30961404
[No Abstract] [Full Text] [Related]
24. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
[TBL] [Abstract][Full Text] [Related]
25. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
[No Abstract] [Full Text] [Related]
26. Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis.
Romero-Jimenez RM; Escudero-Vilaplana V; Baniandres Rodriguez O; García Martín E; Mateos Mayo A; Sanjurjo Saez M
J Dermatolog Treat; 2018 Dec; 29(8):792-796. PubMed ID: 29676189
[TBL] [Abstract][Full Text] [Related]
27. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.
Talamonti M; Galluzzo M; Chimenti S; Costanzo A
J Am Acad Dermatol; 2016 Feb; 74(2):374-5. PubMed ID: 26775778
[No Abstract] [Full Text] [Related]
28. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
Talamonti M; Galluzzo M; van den Reek JM; de Jong EM; Lambert JLW; Malagoli P; Bianchi L; Costanzo A
Br J Dermatol; 2017 Aug; 177(2):489-496. PubMed ID: 28207934
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.
Saeki H; Ito T; Hayashi M; Fukuchi O; Umezawa Y; Nobeyama Y; Teruya K; Nakagawa H
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1653-5. PubMed ID: 24754476
[No Abstract] [Full Text] [Related]
30. Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.
Almirall M; Rodriguez J; Mateo L; Carrascosa JM; Notario J; Gallardo F
Clin Rheumatol; 2017 Feb; 36(2):439-443. PubMed ID: 27817126
[TBL] [Abstract][Full Text] [Related]
31. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience.
Galluzzo M; D'Adamio S; Silvaggio D; Lombardo P; Massaro A; Egan CG; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2020 Jan; 20(1):95-104. PubMed ID: 31640431
[No Abstract] [Full Text] [Related]
32. Pregnancy during Ustekinumab Treatment for Severe Psoriasis.
Rocha K; Piccinin MC; Kalache LF; Reichert-Faria A; Silva de Castro CC
Dermatology; 2015; 231(2):103-4. PubMed ID: 25790947
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
Egeberg A; Iversen L; Gniadecki R; Hvid L; Dam TN; Bryld LE; Skov L
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1183-1187. PubMed ID: 28273375
[TBL] [Abstract][Full Text] [Related]
34. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
[TBL] [Abstract][Full Text] [Related]
35. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in a solid organ transplanted recipient: A case report.
Richetta A; Marraffa F; Grassi S; Aquila E; Dybala A; Aprile F; Merli M
Australas J Dermatol; 2021 Aug; 62(3):e442-e443. PubMed ID: 33634474
[No Abstract] [Full Text] [Related]
36. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
[No Abstract] [Full Text] [Related]
37. Excellent response to ustekinumab in a 9-year-old girl with severe psoriasis.
González-Barreto RM; Rochet NM; Nevares-Pomales OW; Colón-Fontanez F
Pediatr Dermatol; 2018 Jan; 35(1):e76-e78. PubMed ID: 29205479
[TBL] [Abstract][Full Text] [Related]
38. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.
Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H
J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602
[TBL] [Abstract][Full Text] [Related]
39. Response of superimposed linear psoriasis to ustekinumab: A case report.
Weng HJ; Tsai TF
Indian J Dermatol Venereol Leprol; 2017; 83(3):392-396. PubMed ID: 28366906
[No Abstract] [Full Text] [Related]
40. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.
Savage L; Goodfield M; Horton L; Watad A; Hensor E; Emery P; Wakefield R; Wittmann M; McGonagle D
Arthritis Rheumatol; 2019 Apr; 71(4):626-631. PubMed ID: 30468001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
